Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173470
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cotes Sanchís, Almudena | - |
dc.contributor.author | Gallego, Javier | - |
dc.contributor.author | Hernandez, Raquel | - |
dc.contributor.author | Arrazubi, Virginia | - |
dc.contributor.author | Custodio, Ana | - |
dc.contributor.author | Cano, Juana María | - |
dc.contributor.author | Aguado, Gemma | - |
dc.contributor.author | Macias, Ismael | - |
dc.contributor.author | Lopez, Carlos | - |
dc.contributor.author | López, Flora | - |
dc.contributor.author | Visa, Laura | - |
dc.contributor.author | Garrido, Marcelo | - |
dc.contributor.author | Martínez Lago, Nieves | - |
dc.contributor.author | Fernández Montes, Ana | - |
dc.contributor.author | Limón, María Luisa | - |
dc.contributor.author | Azkarate, Aitor | - |
dc.contributor.author | Pimentel, Paola | - |
dc.contributor.author | Reguera, Pablo | - |
dc.contributor.author | Ramchandani, Avinash | - |
dc.contributor.author | Cacho, Juan Diego | - |
dc.contributor.author | Martín Carnicero, Alfonso | - |
dc.contributor.author | Granja, Mónica | - |
dc.contributor.author | Martín Richard, Marta | - |
dc.contributor.author | Hernández Pérez, Carolina | - |
dc.contributor.author | Hurtado, Alicia | - |
dc.contributor.author | Serra, Òlbia | - |
dc.contributor.author | Buxo, Elvira | - |
dc.contributor.author | Vidal Tocino, Rosario | - |
dc.contributor.author | Jimenez Fonseca, Paula | - |
dc.contributor.author | Carmona Bayonas, Alberto | - |
dc.date.accessioned | 2021-01-28T07:55:05Z | - |
dc.date.available | 2021-01-28T07:55:05Z | - |
dc.date.issued | 2020-07-31 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173470 | - |
dc.description.abstract | Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods: The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). Results: 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's tau = 0.613), lower in those subjects who received second-line (Kendall's tau = 0.539), especially with ramucirumab+CT (Kendall's tau = 0.413). Conclusion: This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines. | - |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0235848 | - |
dc.relation.ispartof | PLoS One, 2020, vol. 15, num. 7, p. e0235848 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0235848 | - |
dc.rights | cc by (c) Cotes Sanchís et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer d'estómac | - |
dc.subject.classification | Qualitat de vida | - |
dc.subject.classification | Metàstasi | - |
dc.subject.other | Stomach cancer | - |
dc.subject.other | Quality of life | - |
dc.subject.other | Metastasis | - |
dc.title | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-01-25T08:08:08Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32735623 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
SanchisAC.pdf | 1.62 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License